ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN)

ProShare Advisors LLC acquired a new position in Design Therapeutics, Inc. (NASDAQ:DSGN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,525 shares of the company’s stock, valued at approximately $71,000.

Other hedge funds have also bought and sold shares of the company. Invesco Ltd. purchased a new position in shares of Design Therapeutics in the fourth quarter valued at about $71,000. China Universal Asset Management Co. Ltd. bought a new position in Design Therapeutics in the fourth quarter worth approximately $74,000. Kennedy Capital Management LLC bought a new position in Design Therapeutics in the fourth quarter worth approximately $88,000. Intech Investment Management LLC purchased a new stake in Design Therapeutics during the fourth quarter worth $109,000. Finally, Wells Fargo & Company MN lifted its holdings in Design Therapeutics by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 18,428 shares of the company’s stock worth $114,000 after buying an additional 4,013 shares during the period. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Price Performance

NASDAQ DSGN opened at $4.01 on Wednesday. The stock’s fifty day moving average price is $3.68 and its 200 day moving average price is $4.71. Design Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $7.77. The company has a market cap of $227.64 million, a price-to-earnings ratio of -4.72 and a beta of 1.77.

Design Therapeutics (NASDAQ:DSGN) last posted its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). Research analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.